1. ALLA AKTIER
  2. NYHETER
  3. AROCELL

AroCell

Nyheter AroCell Nyheter alla bolag

AroCell publishes the Annual Report for 2023

MARKN.

AroCell hereby announces that the annual report for 2023 has now been published and is available on the company’s website: www.arocell.com.

The annual report is available on the following link: www.arocell.com/investors/financial-reports/
 

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

Årsredovisning 2023

Datum 2024-04-12, kl 08:00
Källa MFN
Bifogade filer
Årsredovisning 2023
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet